DexCom, Inc. — FY2016 Form 10-K
Reporting period: Fiscal year ended December 31, 2016. Filed February 28, 2017. The filing reports full-year results and unaudited quarterly results, including Q4; it is not a standalone Q4 filing. Amounts below are in millions of dollars unless stated otherwise.
Business context
DexCom develops and sells continuous glucose monitoring (CGM) systems, primarily the G4 PLATINUM and G5 Mobile, and recurring disposable sensors. Sensor sales represented approximately 70% of revenue. The FDA approved a non-adjunctive indication for G5 Mobile in December 2016, permitting its use for treatment decisions in place of routine confirmatory finger-stick tests, while retaining two daily finger-stick calibrations.
Financial performance
| Metric | FY2016 | FY2015 | Change |
|---|---|---|---|
| Total revenue | $573.3 | $402.0 | +$171.3, approximately 43% |
| Gross profit | $378.4 | $278.4 | +$100.0 |
| Gross margin | 66.0% | 69.3% | Down 3.3 percentage points |
| Research and development | $156.1 | $137.5 | +$18.6 |
| Selling, general and administrative | $286.2 | $198.0 | +$88.2 |
| Operating loss | $(63.9) | $(57.1) | Loss widened $6.8 |
| Net loss | $(65.6) | $(57.6) | Loss widened $8.0 |
| Net loss per share | $(0.78) | $(0.72) | |
| Operating cash flow | $56.2 | $49.0 | +$7.2 |
| Capital expenditures | $55.7 | $33.3 | +$22.4 |
Revenue growth primarily reflected higher sensor volume as the installed customer base expanded, as well as durable-system sales. Higher operating expenses—particularly SG&A—more than offset gross-profit growth. Gross margin declined, partly due to lower-margin G5 transmitter mix and costs associated with the receiver issue. FY2016 included $110.8 million of share-based compensation, a significant noncash expense.
Q4 2016: Revenue was $171.2 versus $130.8 in Q4 2015; gross profit was $116.7 versus $91.2; operating expenses were $122.8 versus $89.6; and net loss was $7.4 versus net income of $1.5. Quarterly cash flow is not clearly provided in the filing text.
Liquidity, debt and balance sheet
At year-end, cash and cash equivalents were $94.5; short-term marketable securities were $29.2; working capital was $177.6; total assets were $402.8; and stockholders’ equity was $283.8. Operating cash flow exceeded net loss, substantially reflecting noncash expenses, including share-based compensation. Investing cash outflow was $55.9 and financing cash inflow was $8.1.
DexCom had no outstanding borrowings under its $200 million revolving credit facility at December 31, 2016, and repaid the remaining balance of its prior term loan during 2016. The balance sheet reports $16.6 of other liabilities, including a $6.0 million financing obligation related to the Mesa build-to-suit facility; the filing does not present this entire amount as conventional debt. Management said available liquidity, expected operating cash contributions and the revolver were expected to fund anticipated needs through at least February 28, 2018.
Material changes, outlook and risks
- FY2016 cost of sales included $3.5 million of excess and obsolete receiver inventory tied primarily to the February 2016 audible-alarm and alert customer notification, classified as a voluntary FDA Class 1 recall. Warranty charges rose to $25.0 million from $9.0 million in 2015; the year-end warranty accrual was $9.8 million.
- Management expects continued net losses while investing in commercialization, research and development, and infrastructure. No specific revenue or earnings guidance is provided in the supplied filing text.
- DexCom was constructing a second manufacturing facility in Mesa, Arizona, with production anticipated to begin in 2018, subject to completion and regulatory qualification. FY2016 capital spending was elevated, and future capacity and timing remain execution risks.
- Medicare established a therapeutic-CGM durable-medical-equipment classification in January 2017, subject to coverage conditions; G4 PLATINUM was not included. Medicare access and reimbursement therefore remained conditional, not assured.
- Key risks include reimbursement restrictions, manufacturing scale-up and single-source suppliers, competition, regulatory approval and product safety, and dependence on distributors. Byram and Edgepark accounted for approximately 17% and 11% of FY2016 revenue, respectively.
- AgaMatrix patent litigation was unresolved; DexCom stated the outcome and potential fees could not be assessed and accrued no amounts. The FDA’s response to the alarm notification actions was still pending.
Important facts for investors to verify
- Whether sensor growth and customer adoption can sustain revenue expansion while operating expenses and losses increase.
- Whether gross margins recover from the FY2016 decline and elevated warranty and product-related costs.
- Implementation of Medicare coverage conditions and the extent of actual reimbursement and uptake for G5 Mobile.
- Completion, qualification and production ramp of the Mesa facility, and whether capacity meets demand without disrupting supply.
- Current status and financial exposure from the FDA alarm matter, AgaMatrix litigation, and distributor concentration.
- Liquidity outlook against continued losses, capital spending, lease commitments and the $200 million revolving facility’s covenants.